✦ LIBER ✦

PCN67 Erlotinib as Second Line Treatment for Advanced Non-Small Cell Lung Cancer (NSCLC): Economic Modeling (EM) results

✍ Scribed by Santos, E.A.V.; Buschinelli, C.T.; Ferracini, M.; Pepe, C.; Estanislao, M.

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

PCN9 ERLOTINIB IN NON-SMALL CELL LUNG CA

✍ A Gabriel; O Pirk; W Kotowa 📂 Article 📅 2006 🏛 John Wiley and Sons 🌐 English ⚖ 72 KB

PCN3 ECONOMIC IMPACT OF SECOND- ANDTHIRD

✍ C Chouaid; A Vergnenegre; A Moser; C Coudray-Omnes 📂 Article 📅 2007 🏛 John Wiley and Sons 🌐 English ⚖ 74 KB

PCN10 COST-EFFCTIVENESS ANALYSIS OF ERLO

✍ TC Hsia; GC Chang; YM Chen; MC Lin; WC Su; CM Tsai; CM Tsai; L Yang; J Creeden 📂 Article 📅 2007 🏛 John Wiley and Sons 🌐 English ⚖ 71 KB

PCN36 ECONOMIC EVALUATION OF ERLOTINIB,

✍ S Capri; A Morabito; G Carillio; F Grossi; R Longo; G Cerea; F Rossetti 📂 Article 📅 2007 🏛 John Wiley and Sons 🌐 English ⚖ 68 KB

PCN89 Economic Evaluation of Erlotinib a

✍ Lechuga, D.; Alva, M.; Sanchez-Kobashi, R.; Gay, J.G. 📂 Article 📅 2012 🏛 John Wiley and Sons 🌐 English ⚖ 72 KB

Erlotinib treatment results in patients

✍ Salajka, F.; Pešek, M.; Skřičková, J.; Zatloukal, P.; Koubková, L.; Grygárková, 📂 Article 📅 2012 🏛 Elsevier Science 🌐 English ⚖ 60 KB